Table 1 Baseline participant characteristics
Total (N = 92) | Placebo (N = 31) | CFE400 (N = 30) | CFE500 (N = 31) | P-value | |
|---|---|---|---|---|---|
Male/Female (N) | 52/40 | 20/11 | 15/15 | 17/14 | 0.506 |
Age (years) | 24 ± 5 | 24 ± 5 | 24 ± 5 | 23 ± 4 | 0.361 |
Weight (kg) | 70.8 ± 11.0 | 71.9 ± 11.5 | 68.7 ± 11.7 | 71.7 ± 9.8 | 0.445 |
Height (m) | 1.77 ± 0.1 | 1.77 ± 0.1 | 1.76 ± 0.1 | 1.79 ± 0.1 | 0.275 |
BMI (kg/m2) | 22.4 ± 2.2 | 23.0 ± 2.0 | 22.2 ± 2.3 | 22.2 ± 2.2 | 0.262 |
Exercise time (h) | 7.94 ± 4.15 | 8.11 ± 4.6 | 7.63 ± 3.6 | 8.07 ± 4.4 | 0.885 |
Average Power (W) | 543 ± 143 | 547 ± 141 | 511 ± 134 | 571 ± 149 | 0.259 |
5 s Peak Power (W) | 721 ± 215 | 726 ± 228 | 675 ± 200 | 762 ± 214 | 0.286 |
Time to peak (s) | 1.73 ± 2.2 | 1.57 ± 3.0 | 2.37 ± 1.9 | 1.28 ± 1.1 | 0.131 |
Heart Rate Maximum (BPM) | 173 ± 11 | 171 ± 9 | 173 ± 14 | 173 ± 10 | 0.699 |